IN THE CLAIMS

Please amend claims 1 and 25 to read as follows:

1. (Currently Amended) A composition for inducing an immune response, comprising micelles or micro-aggregates wherein each micelle or micro-aggregate comprises:

more than one ~~a~~ first lipopeptide comprising at least one CTL antigenic determinant and at least one lipid unit, and

a second lipopeptide comprising at least one helper T antigenic determinant and at least one lipid unit.

2. (Previously Presented) A composition according to claim 1 wherein the first and second lipopeptides each comprise one or more C_4-C_{18} lipid units.

3. (Previously Presented) A composition according to Claim 1 wherein the first and second lipopeptides each comprise one or two C_4-C_{18} lipid chains linked by a covalent bond to one or two amino acids of the respective lipopeptide.

4. (Previously Presented) A composition according to Claim 1 wherein the lipid units of the lipopeptides each comprise two palmitic acid chains linked to a lysine through an NH_2 group of said lysine.

5. (Previously Presented) A composition according Claim 1 wherein the lipid units of each lipopeptide comprises one or more of: a residue of palmitic acid, 2-aminohexadecanoic acid, oleic acid, linoleic acid, linolenic acid, pimelautide, trimexautide, or a derivative of cholesterol.

6. (Previously Presented) A composition according to Claim 1 wherein the non-lipid part of the each of the first and second lipopeptides comprises between 10 and 100 amino acids.

7. (Previously Presented) A composition according to Claim 1 wherein the helper T antigenic determinant is a multivalent antigenic determinant.

8. (Withdrawn) A composition according to Claim 1, wherein the helper T antigenic determinant is the peptide 830-843 of the tetanus toxin with the following sequence: QYIKANSKFIGITE (SEQ ID NO: 1).

9. (Previously Presented) A composition according to Claim 1 wherein the helper T antigenic determinant comprises the antigenic determinant of hemagglutinin or the PADRE antigenic determinant.

10. (Previously Presented) A composition according to Claim 1 wherein the lipopeptides comprise at least one CTL antigenic determinant selected from the group consisting of a specific protein of melanoma, a protein from HIV, a protein from HBV, a protein from papillomavirus, protein p53 and a specific protein of *Plasmodium falciparum*.

11. (Previously Presented) A composition according to Claim 1 wherein said micelles or micro-aggregates comprise one or more of the following lipopeptides:

GAG 17 EKIRLRPGGKKKYKLKHIVK(Pam)-NH_2 (SEQ ID No: 31)

GAG 253 NPPIPVGEIYKRWIILGLNKIVRMYSPTSILDK(Pam)-NH_2 (SEQ ID No: 6)

POL 325 AIFQSSMTKILEPFRKQNPDIVIYQYMDDLYK(Pam)-NH_2 (SEQ ID No: 32)

NEF 66 VGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLK(Pam)-NH_2 (SEQ ID No: 2)

NEF 116 HTQGYFPDWQNYTPGPGVRYPLTFGWLYKLK(Pam)-NH_2 (SEQ ID No: 33)

TT Ac-QYIKANSKFIGITELKKK(Pam)-NH_2 (SEQ ID No: 30).

12. (Withdrawn) A composition according to Claim 1 wherein said micelles or micro-aggregates comprise the following lipopeptides:

LSA3 CT1 LLSNIEEPKENIIDNLLNNIK(Pam)-NH_2 (SEQ ID NO. 34)

LSA3 NR1 Ac-DELFNELLNSVDVNGEVKENILEESQK(Pam)-NH_2 (SEQ ID NO. 35)

LSA3 NRII Ac-LEESQVNDDIFNSLVKSVQQEQQHNVK(Pam)-NH_2 (SEQ ID NO. 36)

LSA3 RE K(Pam)VESVAPSVEESVAPSVEESVAENVEESVAENV-NH_2 (SEQ ID NO. 37)

13. (Previously Presented) A method for the production of a vaccine for inducing an immune response comprising micelles or aggregates according to Claim 1.

14. (Previously Presented) A method according to Claim 13, said immune response being induced against HIV, HBV, papilloma virus, p53, melanoma, or *Plasmodium falciparum.*

15. (Previously Presented) A pharmaceutical composition comprising a pharmacologically effective dose of micelles or micro-aggregates according to Claim 1 and a pharmaceutically compatible vehicle.

16. (Previously Presented) A vaccine comprising micelles or micro-aggregates according to Claim 1 and a physiologically acceptable vehicle.

17. (Previously Presented) A method for producing micelles or micro-aggregates according to Claim 1, comprising the following steps:

- dispersing each of the constituent lipopeptides in a solution of concentrated acetic acid of about 80% concentration then
- mixing the solutions thus obtained.

18. (Previously Presented) A method according to Claim 17 wherein the dispersing of the lipopeptides dissolved in acetic acid is confirmed by a two-dimensional nuclear magnetic resonance method.

19. (Previously Presented) A method for inducing an immune response against a particular antigen in an individual comprising administering micelles or micro-aggregates according to Claim 1 to the individual.

20. (Previously Presented) A method of immunizing an individual against a pathogenic agent comprising the administration of micelles or micro-aggregates according to Claim 1 to the individual.

21. (Previously Presented) A method according to Claim 19, wherein the pathogenic agent is HIV, HBV, papillomavirus, melanoma or *plasmodium falciparum*, and wherein the antigen is an antigen of one of said pathogenic agents, or p53.

22. (Previously Presented) A composition according to Claim 1, wherein the at least one lipid unit in the second lipopeptide is different from any lipid unit in the first lipopeptide.

23. (Previously Presented) A composition according to Claim 6, wherein the non-lipid part of the lipopeptides, comprising the antigenic determinants, comprises between 10 and 50 amino acids.

24. (Previously Presented) A method according to Claim 20, wherein the pathogenic agent is HIV, HBV, papillomavirus, melanoma, or *Plasmodium falciparum*, and wherein the antigen is an antigen of one of said pathogenic agents, or p53.

25. (Currently Amended) A composition according to Claim 1 ~~Claim 8~~, wherein the helper T antigenic determinant is the peptide 830-843 of the tetanus toxin with the following sequence: QYIKANSKFIGITE (SEQ ID No: 1).